Camilo Colaco

ImmunoBiology

Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.

dont miss

The immunobiology of immunotherapy

Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.

EVEN MORE SEMINARS

  • Professor A. Graham Pockley: Speaking at the Oncology Convention

    Professor A. Graham Pockley
    multimmune GmbH / Nottingham Trent University

    A new era of cancer therapeutics?

  • Mohamed Torky: Speaking at the Oncology Convention

    Mohamed Torky
    Hospital Germans Trias i pujol. Barcelona. Spain

    Role of Radial-EBUS in diagnosis of lung cancer.

  • Mr Naga Venkatesh Jayanthi MD, FRCS: Speaking at the Oncology Convention

    Mr Naga Venkatesh Jayanthi MD, FRCS
    Bupa - Consultant Surgeon

    Minimal Invasive Oesophagectomy – where are we going?

  • Chris Curtis: Speaking at the Oncology Convention

    Chris Curtis
    The Swallows Head & Neck Cancer Charity

    A patient’s journey ‘Cancer to the palace in 6yrs’

  • Emlyn Samuel: Speaking at the Oncology Convention

    Emlyn Samuel
    Cancer Research UK

    Brexit: getting the best outcome for research and patients